Eli Lilly and Novo Nordisk are competing over $150B in future obesity drug sales. But behind the ad lawsuits and pipeline headlines, there\u2019s a quieter battle: who gets to hire and keep the scientists, engineers, and executives who actually build this market.
\nThe numbers tell two very different stories right now:<\/p>\n
$27B pledged for four new U.S. manufacturing sites \u2013 3,000 permanent jobs for engineers, scientists, and lab technicians, plus ~10,000 construction jobs<\/p>\n
$50B+ in U.S. capital investment since 2020, $21B+ of it in Indiana alone<\/p>\n
A new $4.5B injection into its Lebanon, Indiana LEAP campus, home to the Lilly Medicine Foundry (~400 new science\/engineering roles)<\/p>\n
A Boston R&D hub (Lilly Seaport Innovation Center) built specifically around RNA\/DNA therapeutics talent<\/p>\n
CEO David Ricks was pharma\u2019s highest-paid CEO in 2025 at $36.7M \u2013 a 26% raise<\/p>\n
Cut 9,000 jobs (11% of its workforce) in 2025 as Lilly ate into its obesity market lead<\/p>\n
New CEO Mike Doustdar\u2019s first major move: hiring freezes in non-critical areas, then a five-day return-to-office mandate to \u201cmove faster\u201d<\/p>\n
Boardroom churn \u2013 the Novo Nordisk Foundation moved to retake board control, several independent directors quit, and a candidate (Pfizer\u2019s former R&D chief Mikael Dolsten) withdrew from a board race<\/p>\n
Chief Medical Officer Dr. Zachary Roberts departed to become CEO of Allogene Therapeutics<\/p>\n
Former CEO Lars Fruergaard J\u00f8rgensen was ousted after Novo stock fell ~52% from its peak \u2013 still exiting with ~$19.5M in pay<\/p>\n
Deloitte data shows obesity treatments have overtaken oncology as pharma\u2019s biggest contributor to late-stage pipeline value \u2013 the first time in 16 years oncology hasn\u2019t led. That means metabolic-disease scientists are now the most in-demand specialists in the industry, and it\u2019s not just a two-horse race: Viking Therapeutics, Kailera, Pfizer, and a wave of Chinese biotechs are all competing for the same limited pool of GLP-1 expertise.<\/p>\n
Even the drugs themselves have become a recruiting tool. Nearly a third of employees say they\u2019d switch jobs for GLP-1 coverage, and employers increasingly frame it as a retention lever, not just a benefit line item.<\/p>\n
The historical irony: Novo Nordisk\u2019s own predecessor companies spent decades poaching researchers from each other before merging to stop competing for the same talent pool internally. Now Novo finds itself on the losing end of a very similar dynamic \u2013 this time with Lilly on the other side.<\/p>\n
Lilly is building. Novo is rebuilding. And the scientists, engineers, and executives who choose between them may shape who ultimately leads the GLP-1 race.<\/p>\n","protected":false},"excerpt":{"rendered":"
Eli Lilly and Novo Nordisk are competing over $150B in future obesity drug sales. But behind the ad lawsuits and pipeline headlines, there\u2019s a quieter battle: who gets to hire and keep the scientists, engineers, and executives who actually build this market. The numbers tell two very different stories right now: \ud835\udddf\ud835\uddf6\ud835\uddf9\ud835\uddf9\ud835\ude06 \ud835\uddf6\ud835\ude00 \ud835\uddf6\ud835\uddfb \ud835\uddf3\ud835\ude02\ud835\uddf9\ud835\uddf9 […]<\/p>\n","protected":false},"author":2,"featured_media":11921,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-11246","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-talent-insights"],"_links":{"self":[{"href":"https:\/\/softlinkxdev.com\/execruits\/wp-json\/wp\/v2\/posts\/11246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/softlinkxdev.com\/execruits\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/softlinkxdev.com\/execruits\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/softlinkxdev.com\/execruits\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/softlinkxdev.com\/execruits\/wp-json\/wp\/v2\/comments?post=11246"}],"version-history":[{"count":16,"href":"https:\/\/softlinkxdev.com\/execruits\/wp-json\/wp\/v2\/posts\/11246\/revisions"}],"predecessor-version":[{"id":12429,"href":"https:\/\/softlinkxdev.com\/execruits\/wp-json\/wp\/v2\/posts\/11246\/revisions\/12429"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/softlinkxdev.com\/execruits\/wp-json\/wp\/v2\/media\/11921"}],"wp:attachment":[{"href":"https:\/\/softlinkxdev.com\/execruits\/wp-json\/wp\/v2\/media?parent=11246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/softlinkxdev.com\/execruits\/wp-json\/wp\/v2\/categories?post=11246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/softlinkxdev.com\/execruits\/wp-json\/wp\/v2\/tags?post=11246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}